20:06 , Apr 24, 2019 |  BC Extra  |  Financial News

Why Satsuma investors see room for another migraine therapy

While a new class of drugs has captured most of the attention around migraine treatments, Satsuma's investors believe there's room in the marketplace for a new formulation of an old drug. Satsuma Pharmaceuticals Inc. (South...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
18:37 , Apr 4, 2019 |  BC Extra  |  Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

FDA Commissioner Scott Gottlieb will return to the American Enterprise Institute as a resident fellow after he leaves the agency. His last day at FDA is Friday. Gottlieb expects to work part-time at AEI, where...
21:35 , Mar 18, 2019 |  BC Extra  |  Company News

Biohaven spends $105M for faster review of oral CGRP inhibitor

Biohaven bought a $105 million Priority Review voucher from GW Pharmaceuticals to expedite the entry of its oral migraine therapy into the CGRP inhibitor market. It plans to use the voucher on an NDA for...
21:05 , Jan 10, 2019 |  BC Innovations  |  Emerging Company Profile

Kleo: small molecule immuno-oncology

Kleo Pharmaceuticals Inc. is tapping small molecules' advantages over biologics by synthesizing compounds that mimic or modify the functions of antibodies as cancer immunotherapies. The company spun out of Yale University in 2015 with IP...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:20 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Biohaven nets $125M ahead of NDA submissions

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHNV) raised $125 million Dec. 12 through the sale of 3.3 million shares at $37.25 in an upsized follow-on. Following positive Phase III data reported this month for rimegepant for...
18:37 , Dec 13, 2018 |  BC Extra  |  Financial News

Biohaven nets $125M ahead of NDA submissions

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHNV) raised $125 million late Wednesday through the sale of 3.3 million shares at $37.25 in an upsized follow-on. Following positive Phase III data reported this month for rimegepant for...
17:58 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Biohaven's orally dissolving tablet meets in Phase III for acute migraine

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) said its orally dissolving tablet (ODT) formulation of rimegepant met the co-primary endpoints in the Phase III BHV3000-303 trial for the acute treatment of migraine. The company updated its...
20:13 , Dec 3, 2018 |  BC Extra  |  Clinical News

Biohaven's orally dissolving tablet meets in Phase III for acute migraine

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) added $8.66 (25%) to $42.65 on Monday after reporting that its orally dissolving tablet (ODT) formulation of rimegepant met the co-primary endpoints in the Phase III BHV3000-303 trial for...